Osteosarcoma Market to Grow Rapidly by 2032, Assesses DelveInsight | Leading Companies - MedPacto, Y-mAbs, QSAM, BioEclipse, Cellectar Biosciences, BioAtla, Salarius, Jazz, Fusion, Sumitomo Pharma Oncology
20. September 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Osteosarcoma Market to Grow Rapidly by 2032, Assesses DelveInsight | Leading Companies - MedPacto, Y-mAbs, QSAM, BioEclipse, Cellectar Biosciences,...
DelveInsight Evaluates a Robust Osteosarcoma Pipeline as 30+ Influential Pharma Players to Set Foot in the Domain
21. November 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- DelveInsight Evaluates a Robust Osteosarcoma Pipeline as 30+ Influential Pharma Players to Set Foot in the Domain The prevalence of Osteosarcoma has...
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
26. Oktober 2022 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Global Bone Cancer Treatment Market to Reach $1.8 Billion by 2031: Says AMR
21. Oktober 2022 08:51 ET
|
Allied Market Research
Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Bone Cancer Treatment Market was estimated at $1.2 billion in 2021 and is...
QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
02. Februar 2022 08:30 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer
01. Dezember 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma
18. August 2021 09:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment...
Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma
09. März 2021 07:00 ET
|
Allarity Therapeutics A/S
- Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release Hørsholm, Denmark (9 March 2021) – Allarity...
QSAM Biosciences Issues Letter from New CEO; Presents Opportunities Ahead for Company
24. November 2020 09:00 ET
|
QSAM Biosciences Inc.
Palm Beach, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The recently appointed Chief Executive Officer of QSAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided in the following letter to...